Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5∗3 genotype in Chinese renal transplant recipients

Acta Pharmacologica Sinica

Volumn 37, Issue 4, 2016, Pages 555-560

  Luo, Xi ^a   Zhu, Li Jun ^a   Cai, Ning Fang ^b   Zheng, Li Yun ^a   Cheng, Ze Neng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Department of Radiology   (China)

Author keywords

Chinese renal transplant recipients; CYP3A phenotype; CYP3A5 3 genotype; Tacrolimus

Indexed keywords

6BETA HYDROXYCORTISONE; 6BETA HYDROXYHYDROCORTISONE; CORTISONE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DEXAMETHASONE; HYDROCORTISONE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG; 6 BETA-HYDROXYCORTISOL; 6 BETA-HYDROXYCORTISONE; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CHINESE; DRUG METABOLISM; FEMALE; GENOTYPE; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; URINALYSIS; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; GENETICS; METABOLISM; URINE;

ASIAN CONTINENTAL ANCESTRY GROUP; CORTISONE; CYTOCHROME P-450 CYP3A; HUMANS; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TACROLIMUS;

EID: 84962869309     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2015.163     Document Type: Article

References (14)

1. Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 2006; 112: 184-98.
2. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997; 27: 201-14.
3. Feng Y, Zhang S, Poloyac S, Strom S, Venkataramanan R. Determination of 13-O-demethyl tacrolimus in human liver microsomal incubates using liquid chromatography-mass spectrometric assay (LC-MS). J Chromatogr B Analyt Technol Biomed Life Sci 2005; 821: 31-7.
4. Oleson L, von Moltke LL, Greenblatt DJ, Court MH. Identification of polymorphisms in the 3?-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism. Xenobiotica 2010; 40: 146-62.
5. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-91.
6. de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance inrenal transplant patients. Clin Pharmacol Ther 2012; 92: 366-75.
7. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-74.
8. Galteau MM, Shamsa F. Urinary 6?-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 2003; 59: 713-33.
9. Peng CC, Templeton I, Thummel KE, Davis C, Kunze KL, Isoherranen N. Evaluation of 6?-hydroxycortisol, 6?-hydroxycortisone and their combination as endogenous probes for inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 2011; 89: 888-95.
10. Luo X, Li XM, Hu ZY, Cheng ZN. Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism. Acta Pharmacol Sin 2009; 30: 1323-9.
11. Zheng L, Luo X, Zhu L, Xie W, Liu S, Cheng Z. Simultaneous determination of cor tisol, cor tisone, 6?-hydroxycor tisol and 6?-hydroxycortisone by HPLC. J Chromatogr Sci 2015; 53: 451-5.
12. Katz DA, Grimm DR, Cassar SC, Gentile MC, Ye X, Rieser MJ, et al. CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin Pharmacol Ther 2004; 75: 516-28.
13. Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 2007; 81: 228-34.
14. Anglicheau D, Flamant M, Schlageter MH, Martinez F, Cassinat B, Beaune P, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003; 18: 2409-14.